Viatris Believes Eylea Biosimilar Candidate Is First To Reach US FDA’s Desk
As Viatris Discloses ‘Challenging’ Orencia Biosimilar Is Part Of Pipeline Again
Executive Summary
Viatris provided several key updates for its biosimilar pipeline during the company’s Q3 earnings call, including for its biosimilar Eylea and Botox candidates, as well as disclosing another key early-stage asset.
You may also be interested in...
Biocon Gets A New Group CEO As Aflibercept Approval Arrives
Biocon has named Peter Bains as its new group CEO, as the firm’s Biocon Biologics business confirmed that its aflibercept biosimilar to Eylea had become the first to receive a formal European approval.
Questions Swirl Around US Aflibercept With Biocon Decision Imminent
Biocon’s ongoing legal battle with Regeneron over US patents shielding Eylea was discussed by the originator at a pair of recent healthcare conferences, with a decision due any day.
Beyond Viatris: Kiran Mazumdar-Shaw Talks Next Steps For Biocon Biologics
As Biocon Biologics completes its integration of the biosimilars front-end business that it acquired from former partner Viatris, Biocon founder and chairperson Kiran Mazumdar-Shaw talks to Generics Bulletin about how the firm is now capturing the full value of its biosimilars, while also looking at expanding into new markets previously unserved by Viatris.